Physician profile
Ryan Bogner
NPI 1225440324
$1,730.73
in general payments reported to CMS, 2019-2025
21 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2022: $181 · 2023: $442 · 2024: $438 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.00 | 2019-2024 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $188.99 | 2019-2023 | |
| Janssen Biotech, INC. | $162.29 | 2023-2025 | Tremfya |
| Organogenesis INC. | $151.09 | 2023-2024 | Puraply Am, Puraply |
| Genentech USA, INC. | $127.74 | 2019 | |
| Triad Life Sciences INC. | $79.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.48 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $61.04 | 2019-2025 | Anzupgo, Adbry |
| Lilly USA, LLC | $43.38 | 2023 | Taltz, Olumiant |
| Ucb, INC. | $42.15 | 2019-2024 | Bimzelx |
| Amgen INC. | $42.00 | 2019-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $41.71 | 2023 | Dupixent |
| Genzyme Corporation | $27.59 | 2022 | |
| Biofrontera INC. | $21.11 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.29 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.76 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.40 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $14.03 | 2025 | Nemluvio |
| Convatec INC. | $13.67 | 2025 | |
| Almirall LLC | $13.10 | 2024 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bogner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.